King Saud bin Abdulaziz University for Health Sciences, P.O. Box: 65362, Jeddah 21556, Saudi Arabia; King Abdullah International Medical Research Centre, Jeddah, Saudi Arabia.
Princess Noorah Oncology Centre, King Abdulaziz Medical City, Jeddah, Saudi Arabia; King Abdullah International Medical Research Centre, Jeddah, Saudi Arabia; King Saud bin Abdulaziz University for Health Sciences, P.O. Box: 65362, Jeddah 21556, Saudi Arabia.
J Infect Public Health. 2020 Aug;13(8):1176-1180. doi: 10.1016/j.jiph.2020.02.001. Epub 2020 Mar 26.
Cytomegalovirus (CMV) is a rare cause of prolonged febrile neutropenia (PFN) among pediatric oncology patients, especially in non-stem cell transplant setting (Non-SCTS). Infectious Diseases Society of America (IDSA) guidelines stated briefly that neutropenia is not considered as an indication of CMV re-activation, and thus preventive strategies are not needed; however, multiple studies pressed on the need to treat CMV viremia among patients with PFN even when there is no evidence of end-organ involvement. Therefore, this study aimed to prospectively investigate the significance of CMV as a cause of PFN among pediatric oncology patients in a Non-SCTS.
This was a prospective cohort study that was done at Princess Norah Oncology Center, King Abdulaziz Medical City in Jeddah, Saudi Arabia. CMV viral load was monitored weekly once the subject was identified as a case of PFN until resolution. Subjects and treating physicians were blinded to CMV viral load results.
The data of 27 PFN episodes (48% males) were analyzed. The incidence of CMV viremia was reported as 29.6%. Both CMV positive and negative episodes of PFN had similar rate of spontaneous resolution (p=0.669), with overall mortality as 105 and 125 per 1000 PFN episodes, respectively. No subject received anti-CMV in the positive CMV group; however, one subject did in the negative group for reasons other than CMV infection.
This study demonstrated that CMV was not a significant cause of PFN in Non-SCTS. CMV also had no significant role in terms of survival and severity of the PFN episode.
巨细胞病毒(CMV)是儿科肿瘤患者发生发热性中性粒细胞减少症(PFN)的罕见原因,尤其是在非造血干细胞移植环境(Non-SCTS)中。美国传染病学会(IDSA)指南简要指出,中性粒细胞减少症不被认为是 CMV 再激活的指征,因此不需要预防性策略;然而,多项研究强调了在没有终末器官受累证据的情况下,即使对于 PFN 患者,也需要治疗 CMV 病毒血症。因此,本研究旨在前瞻性研究 CMV 在 Non-SCTS 中儿科肿瘤患者 PFN 中的致病作用。
这是一项在沙特阿拉伯吉达阿卜杜勒阿齐兹国王医疗城的 Princess Norah 肿瘤中心进行的前瞻性队列研究。一旦患者被确定为 PFN,每周监测 CMV 病毒载量,直至恢复正常。患者和治疗医生对 CMV 病毒载量结果不知情。
分析了 27 例 PFN 发作(48%为男性)的数据。CMV 病毒血症的发生率为 29.6%。CMV 阳性和阴性 PFN 发作的自发缓解率相似(p=0.669),总死亡率分别为每 1000 例 PFN 发作 105 例和 125 例。CMV 阳性组中没有患者接受抗 CMV 治疗;然而,在 CMV 阴性组中,有 1 例患者因 CMV 感染以外的原因接受了治疗。
本研究表明,CMV 不是 Non-SCTS 中 PFN 的重要原因。CMV 对 PFN 发作的存活和严重程度也没有显著影响。